HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Del Labs

This article was originally published in The Rose Sheet

Executive Summary

Third quarter net sales rose 4.7% to $99.7 mil., driven by solid performance of the company's core brands, including Sally Hansen, which maintained its top ranking in the mass market nail care category, Del Labs reports in an Oct. 28 release. Sally Hansen has a 26% market share in the segment the company notes, citing ACNielsen figures. Despite strong sales, overall earnings fell 8.7% to $4.7 mil., impacted by higher advertising and display costs primarily associated with the launch of the brand's new Healing Beauty color range, which bowed early in the year (1"The Rose Sheet" Dec. 2, 2002, p. 3)...

You may also be interested in...



Sally Hansen Color Cosmetics Bring Healing Positioning To Category

Del Labs is making a full-scale push into the color cosmetics category in January with the launch of Sally Hansen Healing Beauty, a makeup line with a "good-for-you" positioning, Exec VP-Marketing William McMenemy said

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.

 

 

UsernamePublicRestriction

Register

RS011629

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel